Status of Congenital Extrahepatic Portosystemic Shunt

0
0
0

Status of Congenital Extrahepatic Portosystemic Shunt

Congenital extrahepatic portosystemic shunt (CEPS) is a rare but life-threatening vascular anomaly characterized by abnormal connections between the portal venous system and systemic circulation, bypassing the liver. This condition arises from developmental errors during embryogenesis and can lead to severe complications, including liver dysfunction, pulmonary hypertension, hepatic encephalopathy, and multiorgan failure. Understanding its pathology, classification, clinical manifestations, diagnostic approaches, and management strategies is critical for improving patient outcomes.

Pathogenesis and Embryological Basis

The development of CEPS is rooted in disturbances during the embryonic formation of the portal venous system and inferior vena cava (IVC). The portal vein (PV) originates from the vitelline veins, which form a plexus around the duodenum. Persistence of primitive vascular channels due to failed regression or improper anastomosis with the hepatic sinusoids leads to CEPS.

  • Type I CEPS: Caused by excessive degeneration of the vitelline vein ring or failure of the vitelline vein to connect with the hepatic sinus or umbilical vein. This results in the persistence of either the right vitelline vein (draining into the posthepatic IVC) or the left vitelline vein (draining into the IVC or right atrium above the hepatic vein confluence).
  • Type II CEPS: Occurs due to abnormal anastomosis between the vitelline vein and the developing IVC, leading to a hypoplastic PV with a side-to-side shunt.

Classification Systems

CEPS is classified based on anatomical features, shunt location, and portal vein development.

  1. Morgan Classification:

    • Type I (Absent PV): The portal vein is entirely absent.
      • Type Ia: Superior mesenteric vein (SMV) and splenic vein (SV) drain separately into systemic veins.
      • Type Ib: SMV and SV merge into a common trunk before draining into a systemic vein.
    • Type II (Hypoplastic PV): A hypoplastic portal vein coexists with a side-to-side shunt.

  2. Anatomical Variants:

    • Shunt Entrance: Subclassified into IIa (from PV branches), IIb (from PV trunk or spleno-mesenteric confluence), and IIc (from mesenteric, gastric, or splenic veins).
    • Shunt Termination: Extrahepatic (e.g., IVC, renal vein, iliac vein) or persistent ductus venosus.
    • Hepatic Involvement: Graded as mild, moderate, or severe based on intrahepatic PV hypoplasia.

Clinical Manifestations

CEPS presents with heterogeneous symptoms, ranging from asymptomatic cases detected incidentally to life-threatening complications.

  1. Liver-Related Pathology:

    • Reduced Hepatic Perfusion: Leads to hepatic atrophy, steatosis, and nodular regenerative hyperplasia (NRH). Liver nodules occur in 65% of patients, with malignant transformation linked to ischemia, hepatocyte growth factor dysregulation, and arterial hypertension.
    • Hepatic Dysfunction: Impaired ammonia metabolism, coagulation abnormalities, and cholestasis.

  2. Systemic Shunting Effects:

    • Hepatopulmonary Syndrome (HPS): Intrapulmonary shunting causes hypoxemia, detected via contrast echocardiography or pulse oximetry.
    • Portopulmonary Hypertension (PPH): Irreversible pulmonary arterial hypertension with a mortality rate exceeding 50%.
    • Hepatic Encephalopathy (HE): Neurocognitive deficits, including parkinsonism and pyramidal signs, due to ammonia and toxin accumulation.

  3. Associated Congenital Anomalies:

    • Cardiovascular defects (most common), genitourinary malformations, skeletal abnormalities, and syndromes (e.g., Down syndrome, Turner syndrome).

Diagnostic Approaches

Imaging is central to diagnosing CEPS, classifying shunts, and detecting complications.

  1. Ultrasonography:

    • Doppler Ultrasound: Initial screening tool to visualize shunt anatomy, hepatic morphology, and liver nodules. Estimates shunt ratio (shunt flow/total PV flow).
    • Contrast-Enhanced Ultrasound (CEUS): Detects intrapulmonary shunts in HPS.

  2. Magnetic Resonance Imaging (MRI):

    • Gold standard for CEPS evaluation, providing detailed vascular anatomy, hepatic lesions, and brain abnormalities (e.g., white matter atrophy, globus pallidus hyperintensity on T1-weighted images).

  3. Computed Tomography Angiography (CTA):

    • Superior spatial resolution for small vessels; ideal for patients with MRI contraindications.

  4. Angiography and Pressure Measurement:

    • Digital Subtraction Angiography (DSA): Definitive for shunt classification and assessing PV patency.
    • Balloon Occlusion Test: Measures portal pressure during temporary shunt occlusion. A portal pressure >32 mmHg indicates high risk for post-closure complications.

  5. Biochemical and Histopathological Evaluation:

    • Elevated ammonia, liver enzyme derangements, and coagulopathy.
    • Liver biopsy reveals PV hypoplasia and regenerative nodules.

Therapeutic Strategies

Management depends on shunt type, clinical symptoms, and complications.

  1. Type I CEPS:

    • Liver Transplantation: Only curative option due to absent PV.

  2. Type II CEPS:

    • Interventional Closure: First-line for side-to-side shunts.
      • Endovascular Techniques: Coil embolization, balloon-occluded retrograde transvenous obliteration (BRTO).
      • Staged Closure: Required if portal pressure exceeds 32 mmHg during balloon occlusion.
    • Surgical Ligation: Preferred for short, wide shunts unsuitable for endovascular closure.

  3. Complication Management:

    • Hepatic Encephalopathy: Shunt closure reverses hyperammonemia in most cases.
    • Pulmonary Hypertension: Poorly responsive to shunt closure; requires vasodilators and anticoagulation.
    • Hepatic Nodules: Surveillance for malignant transformation; resection if suspicious features arise.

  4. Post-Treatment Surveillance:

    • Monitor for portal hypertension, shunt recurrence, and new collaterals. Long-term imaging (MRI/CTA) and biochemical follow-up are essential.

Prognosis and Challenges

Despite advances, CEPS remains associated with high morbidity. Mortality stems from liver failure, pulmonary complications, and malignancy. Early diagnosis and intervention are critical to prevent irreversible damage. Key challenges include:

  • Diagnostic Complexity: Differentiating Type I from Type II CEPS requires angiographic confirmation.
  • Therapeutic Limitations: Liver transplantation is limited by donor availability and procedural risks.
  • Post-Closure Complications: Thrombosis, neovascular shunts, and persistent portal hypertension necessitate vigilant follow-up.

Conclusion

Congenital extrahepatic portosystemic shunt is a multifaceted disorder demanding multidisciplinary care. Imaging advancements, particularly MRI and angiography, have improved diagnostic accuracy. While interventional and surgical techniques offer therapeutic hope, liver transplantation remains vital for Type I cases. Future research should focus on standardized guidelines, risk stratification, and minimally invasive therapies to enhance outcomes.

doi.org/10.1097/CM9.0000000000001925

Was this helpful?

0 / 0